Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes

Alicia J. Jenkins; Andrzej S. Januszewski; Adrienne Kirby; Christel Hendrieckx; Sybil A. McAuley; Melissa H. Lee; Barbora Paldus; Sara Vogrin; Martin I. de Bock; Mary B. Abraham; Leon A. Bach; Morton G. Burt; Neale D. Cohen; Peter G. Colman; Elizabeth A. Davis; D. J. Holmes-Walker; Joey Kaye; Anthony C. Keech; Kavita Kumareswaran; Richard J. MacIsaac; Roland W. McCallum; Catriona M. Sims; Jane Speight; Stephen N. Stranks; Vijaya Sundararajan; Steven Trawley; Glenn M. Ward; Timothy W. Jones; David N. O'Neal; for the Australian JDRF Closed-Loop Research Group; Philip M. Clarke

doi:10.1111/imj.16567

Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes

Alicia J. Jenkins
, Andrzej S. Januszewski
, Adrienne Kirby
, Christel Hendrieckx
, Sybil A. McAuley
, Melissa H. Lee
, Barbora Paldus
, Sara Vogrin
, Martin I. de Bock
, Mary B. Abraham
, Leon A. Bach
, Morton G. Burt
, Neale D. Cohen
, Peter G. Colman
, Elizabeth A. Davis
, D. J. Holmes-Walker
, Joey Kaye
, Anthony C. Keech
, Kavita Kumareswaran
, Richard J. MacIsaac

Roland W. McCallum, Catriona M. Sims, Jane Speight, Stephen N. Stranks, Vijaya Sundararajan, Steven Trawley, Glenn M. Ward, Timothy W. Jones, David N. O'Neal, for the Australian JDRF Closed-Loop Research Group, Philip M. Clarke

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.

Original language	English
Pages (from-to)	148-153
Number of pages	6
Journal	Internal Medicine Journal
Volume	55
Issue number	1
Early online date	27 Nov 2024
DOIs	https://doi.org/10.1111/imj.16567
Publication status	Published - Jan 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Advocacy
Automated insulin delivery
Clinical trial
Hybrid closed loop pump
Type 1 diabetes

Access to Document

10.1111/imj.16567Licence: In Copyright

Cite this

Jenkins, A. J., Januszewski, A. S., Kirby, A., Hendrieckx, C., McAuley, S. A., Lee, M. H., Paldus, B., Vogrin, S., de Bock, M. I., Abraham, M. B., Bach, L. A., Burt, M. G., Cohen, N. D., Colman, P. G., Davis, E. A., Holmes-Walker, D. J., Kaye, J., Keech, A. C., Kumareswaran, K., ... Clarke, P. M. (2025). Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes. Internal Medicine Journal, 55(1), 148-153. https://doi.org/10.1111/imj.16567

@article{780c8253058547b18e4bab5842f59eed,

title = "Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes",

abstract = "Less than 20\% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.",

keywords = "Advocacy, Automated insulin delivery, Clinical trial, Hybrid closed loop pump, Type 1 diabetes",

author = "Jenkins, \{Alicia J.\} and Januszewski, \{Andrzej S.\} and Adrienne Kirby and Christel Hendrieckx and McAuley, \{Sybil A.\} and Lee, \{Melissa H.\} and Barbora Paldus and Sara Vogrin and \{de Bock\}, \{Martin I.\} and Abraham, \{Mary B.\} and Bach, \{Leon A.\} and Burt, \{Morton G.\} and Cohen, \{Neale D.\} and Colman, \{Peter G.\} and Davis, \{Elizabeth A.\} and Holmes-Walker, \{D. J.\} and Joey Kaye and Keech, \{Anthony C.\} and Kavita Kumareswaran and MacIsaac, \{Richard J.\} and McCallum, \{Roland W.\} and Sims, \{Catriona M.\} and Jane Speight and Stranks, \{Stephen N.\} and Vijaya Sundararajan and Steven Trawley and Ward, \{Glenn M.\} and Jones, \{Timothy W.\} and O'Neal, \{David N.\} and \{for the Australian JDRF Closed-Loop Research Group\} and Jennifer Halliday and Sienna Russell-Green and Husin, \{Hanafi M.\} and Clarke, \{Philip M.\} and Ambler, \{Geoff R.\} and Cameron, \{Fergus J.\} and Fairchild, \{Jan M.\} and King, \{Bruce R.\}",

year = "2025",

month = jan,

doi = "10.1111/imj.16567",

language = "English",

volume = "55",

pages = "148--153",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley \& Sons, Inc",

number = "1",

}

Jenkins, AJ, Januszewski, AS, Kirby, A, Hendrieckx, C, McAuley, SA, Lee, MH, Paldus, B, Vogrin, S, de Bock, MI, Abraham, MB, Bach, LA, Burt, MG, Cohen, ND, Colman, PG, Davis, EA, Holmes-Walker, DJ, Kaye, J, Keech, AC, Kumareswaran, K, MacIsaac, RJ, McCallum, RW, Sims, CM, Speight, J, Stranks, SN, Sundararajan, V, Trawley, S, Ward, GM, Jones, TW, O'Neal, DN, for the Australian JDRF Closed-Loop Research Group & Clarke, PM 2025, 'Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes', Internal Medicine Journal, vol. 55, no. 1, pp. 148-153. https://doi.org/10.1111/imj.16567

Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes. / Jenkins, Alicia J.; Januszewski, Andrzej S.; Kirby, Adrienne et al.
In: Internal Medicine Journal, Vol. 55, No. 1, 01.2025, p. 148-153.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes

AU - Jenkins, Alicia J.

AU - Januszewski, Andrzej S.

AU - Kirby, Adrienne

AU - Hendrieckx, Christel

AU - McAuley, Sybil A.

AU - Lee, Melissa H.

AU - Paldus, Barbora

AU - Vogrin, Sara

AU - de Bock, Martin I.

AU - Abraham, Mary B.

AU - Bach, Leon A.

AU - Burt, Morton G.

AU - Cohen, Neale D.

AU - Colman, Peter G.

AU - Davis, Elizabeth A.

AU - Holmes-Walker, D. J.

AU - Kaye, Joey

AU - Keech, Anthony C.

AU - Kumareswaran, Kavita

AU - MacIsaac, Richard J.

AU - McCallum, Roland W.

AU - Sims, Catriona M.

AU - Speight, Jane

AU - Stranks, Stephen N.

AU - Sundararajan, Vijaya

AU - Trawley, Steven

AU - Ward, Glenn M.

AU - Jones, Timothy W.

AU - O'Neal, David N.

AU - for the Australian JDRF Closed-Loop Research Group

AU - Halliday, Jennifer

AU - Russell-Green, Sienna

AU - Husin, Hanafi M.

AU - Clarke, Philip M.

AU - Ambler, Geoff R.

AU - Cameron, Fergus J.

AU - Fairchild, Jan M.

AU - King, Bruce R.

PY - 2025/1

Y1 - 2025/1

N2 - Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.

AB - Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.

KW - Advocacy

KW - Automated insulin delivery

KW - Clinical trial

KW - Hybrid closed loop pump

KW - Type 1 diabetes

UR - https://www.scopus.com/pages/publications/85210388919

U2 - 10.1111/imj.16567

DO - 10.1111/imj.16567

M3 - Article

AN - SCOPUS:85210388919

SN - 1444-0903

VL - 55

SP - 148

EP - 153

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 1

ER -

Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this